Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02716415
Recruitment Status : Completed
First Posted : March 23, 2016
Last Update Posted : April 24, 2020
Sponsor:
Collaborator:
Calmoseptine, Inc.
Information provided by (Responsible Party):
University of the Philippines

Brief Summary:
The purpose of this study is to compare the efficacy and safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in the treatment of diaper dermatitis among Neonates and Infants.

Condition or disease Intervention/treatment Phase
Diaper Dermatitis Drug: Calmoseptine Ointment Drug: Destin Maximum Strength 40% Zinc Phase 4

Detailed Description:

This is a single-center, randomized, controlled, assessor-blinded clinical trial. Neonates born in UP-PGH or infants (< 1 year of age) in the general pediatric wards for any condition who have diaper dermatitis are recruited and randomized to treatment with either Calmoseptine Ointment or Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste as part of a structured skin care regimen. Each participant has one week total participation, unless withdrawn. Baseline data are collected and study treatment initiated on study entry day. Treatment continued and follow up data collected on six subsequent follow up days. Primary outcome: healing of Diaper Dermatitis after six days of treatment, defined as a Diaper Dermatitis Severity Score of zero attributed by blinded assessment. Secondary outcomes: Diaper Dermatitis Severity Score at each day of treatment; size of affected area; incidence of Candida infection; adverse events.

Zinc Oxide Ointment preparations including Calmoseptine Ointment and Desitin Maximum Strength 40% Diaper Rash Paste have been used to treat diaper dermatitis for many years around the world. There are no known reported hypersensitivities to either product and no reported serious adverse events. As the proposed study is in neonates and infants, as a precaution the evidence relating to the safety and toxicity of individual ingredients were reviewed for the trial protocol prior to commencement.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 319 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants
Study Start Date : March 2015
Actual Primary Completion Date : March 31, 2018
Actual Study Completion Date : March 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rashes

Arm Intervention/treatment
Active Comparator: Calmoseptine Ointment
Calmoseptine Ointment as part of a structured skin care regimen.
Drug: Calmoseptine Ointment

A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.

The regimen includes:

  • regular diaper changing,
  • gentle cleansing
  • application of the trial ointment
Other Name: Calmoseptine

Active Comparator: Destin Maximum Strength 40% Zinc
Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
Drug: Destin Maximum Strength 40% Zinc

A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.

The regimen includes:

  • regular diaper changing,
  • gentle cleansing
  • application of the trial ointment
Other Name: Destin




Primary Outcome Measures :
  1. Healing of diaper Dermatitis [ Time Frame: Assessed on Final day of data collection (Day 6) ]

    Complete healing of Diaper Dermatitis on final study day, as determined by Diaper Dermatitis Severity Scale. Possible score range from zero (0 - clear skin) ti six (6 - severe erythema, all or most of the diaper area affected, with papules and/or pustules, and open skin affecting the dermis). Complete healing is defined as a Diaper Dermatitis Severity Score of zero (0).

    Assessment of the primary outcome used in final analyses will be blinded. For determination of final trial results for the primary outcome, sets of high definition photographs for each patient on each treatment day will be assessed by independent wound, Ostomy and Continence Nursing Certification Board (WOCNB) certified wound care expert assessors based in the USA, who are blinded to treatment allocation, not involved in the study.



Secondary Outcome Measures :
  1. Daily Diaper Dermatitis Severity Score [ Time Frame: Assessed on Day 0, 1, 2, 3, 4, 5, and 6 ]

    Diaper dermatitis severity, assessed as per primary outcome.

    The size of area affected by diaper dermatitis is measured and recorded at baseline (study entry on Day 0) and on each follow up day (Days 1-6). Disposable paper tape measures are used to prevent cross-infection. Where more than one non-contiguous area is affected, each will be measured as described and added together. As the study will include neonates and infants up to one year of age, body size will differ significantly so that an affected area of a similar size may be more serious in one participant than in another. Accordingly, the mean body size and/or weight of treatment groups will be considered and the expression of area affected used in final analyses will be adjusted appropriately.



Other Outcome Measures:
  1. Size of area affected by diaper dermatitis on Days 0-6. [ Time Frame: Measured on Day 0, 1, 2, 3, 4, 5, and 6 ]
    The area will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side (in centimeters).

  2. Adverse Events. [ Time Frame: Recorder on Day 0, 1, 2, 3, 4, 5, and 6 ]
    Non-Serious and serious adverse events judged by physicians to be due to trial participation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 12 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The child participant must be < 1 year of age.
  2. The participant must, upon clinical inspection by an investigator, be assessed to have diaper dermatitis ≥ Grade 2 according to the study's diaper dermatitis severity scale (see "Primary Outcome").
  3. The participant's parent, next of kin or legally acceptable representative agrees to the child's inclusion and signs the informed consent.
  4. The participant's primary physician agrees to inclusion.
  5. There is a reasonable expectation that the participant will be hospitalized for at least 7 days and will be able to complete the study. (NB Study Participant Withdrawal Criteria b - Any participants discharged from hospital by their attending physician before completion of study participation will automatically be withdrawn from the study. Study participation will not under any circumstances lead to delay in a participant's discharge from hospital.)
  6. Participant has no known allergy or history of adverse reaction to any of the ingredients in either product or to any topical preparations or skin care products

Exclusion Criteria:

  1. Participants with a pre-existing full thickness wound within the study area.
  2. Participants with pre-existing active dermatological condition(s), other than DD, which may affect healing or interpretation of trial results. Where uncertainty exists, the Investigators will arrange a consultation with a Consultant Dermatologist.
  3. Participant has a history of recurrent dermatological conditions, other than DD, that may imply difficult healing or affect interpretation of trial results.
  4. Participant has any severe acute or chronic medical condition such that trial participation may constitute a risk, or may interfere with their medical care, or affect interpretation of results, or their attending physician advises against participation.
  5. Participant is on systemic antifungal treatment (eg. Amphotericin B or Fluconazole), topical antifungal treatment and / or systemic or topical corticosteroids.
  6. Participant has in the preceding week been treated with topical agents that may affect healing (e.g. dimethicone based ointments, zinc oxide powder, petroleum jelly)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02716415


Locations
Layout table for location information
Philippines
Philippine General Hospital - University of the Philippines, Manila
Manila, Metro Manila, Philippines, 1000
Sponsors and Collaborators
University of the Philippines
Calmoseptine, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Jacinto Blas Mantaring, MD Department of Pediatrics, Philippine General Hospital UP Manila
Layout table for additonal information
Responsible Party: University of the Philippines
ClinicalTrials.gov Identifier: NCT02716415    
Other Study ID Numbers: 2015-019-01
First Posted: March 23, 2016    Key Record Dates
Last Update Posted: April 24, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of the Philippines:
neonates
infants
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis
Diaper Rash
Skin Diseases
Dermatitis, Irritant
Dermatitis, Contact
Skin Diseases, Eczematous
Menthol
Petrolatum
Zinc Oxide
Antipruritics
Dermatologic Agents
Emollients
Sunscreening Agents
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs